APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

George Lau,Ming-Lung Yu,Grace Wong,Alexander Thompson,Hasmik Ghazinian,Jin-Lin Hou,Teerha Piratvisuth,Ji-Dong Jia,Masashi Mizokami,Gregory Cheng,Guo-Feng Chen,Zhen-Wen Liu,Oidov Baatarkhuu,Ann Lii Cheng,Woon Leung Ng,Patrick Lau,Tony Mok,Jer-Ming Chang,Saeed Hamid,A. Kadir Dokmeci,Rino A. Gani,Diana A. Payawal,Pierce Chow,Joong-Won Park,Simone I. Strasser,Rosmawaiti Mohamed,Khin Maung Win,Tanwandee Tawesak,Shiv Kumar Sarin,Masao Omata
DOI: https://doi.org/10.1007/s12072-021-10239-x
IF: 9.029
2021-08-24
Hepatology International
Abstract:Background & AimHepatitis B reactivation related to the use of immunosuppressive therapy remains a major cause of liver-related morbidity and mortality in hepatitis B endemic Asia-Pacific region. This clinical practice guidelines aim to assist clinicians in all disciplines involved in the use of immunosuppressive therapy to effectively prevent and manage hepatitis B reactivation.MethodsAll publications related to hepatitis B reactivation with the use of immunosuppressive therapy since 1975 were reviewed. Advice from key opinion leaders in member countries/administrative regions of Asian-Pacific Association for the study of the liver was collected and synchronized. Immunosuppressive therapy was risk-stratified according to its reported rate of hepatitis B reactivation.RecommendationsWe recommend the necessity to screen all patients for hepatitis B prior to the initiation of immunosuppressive therapy and to administer pre-emptive nucleos(t)ide analogues to those patients with a substantial risk of hepatitis and acute-on-chronic liver failure due to hepatitis B reactivation.
gastroenterology & hepatology
What problem does this paper attempt to address?